The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead).
The draft report, along with draft voting questions, will be open to public comment for four weeks. Findings contained in this report are preliminary and subject to change based on public comment and further analysis of the evidence.
Both drugs are chimeric antigen receptor T-cell (CAR-T) therapies and were approved earlier this year as potentially curative treatments for certain cancers.
Tisagenlecleucel was approved for patients under age 25 with B-cell precursor acute lymphoblastic leukemia, and is also part of an ongoing study of adults with diffuse large B-cell lymphoma. Axicabtagene ciloleucel is indicated for adults with relapsed or refractory large B-cell non-Hodgkin’s lymphoma.